Soleno Therapeutics, Inc. (NASDAQ: SLNO) was founded on August 25, 1999, formerly known as Capnia, Inc., changed to its current name in May 2017, headquartered in Redwood City, California, USA, with 12 full-time employees. A biotechnology company focused on the development and commercialization of new therapies for the treatment of rare diseases.
Soleno Therapeutics, Inc. (SLNO):
In March 2017, Capnia, Inc. acquired Essentialis, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. The company is committed to the development and commercialization of new therapies for rare diseases.
Soleno Therapeutics’ core commitment is to provide safe and effective products by providing innovative solutions for unmet medical needs. The goal of Soleno Therapeutics is to improve the development of healthcare by continuously improving and evaluating its goals, thereby changing the lives of people all over the world.
Soleno Therapeutics’ main drug candidate, Diazoxide Choline Controlled Release (DCCR), a tablet for the treatment of Prader-Willi syndrome (PWS), is entering advanced clinical development.